Key Highlights

  • Arcus shares ticked up 0.41% to $15.85, against a prior close of $15.78.
  • The stock sits near its 52-week low of $15.63.
  • Third-quarter Revenue was $9 million, down from $26 million a year earlier.
  • The company priced a $250 million stock offering in October.
  • The consensus target is about $41.

Strong Kidney Cancer Data Meets a Weak Share Price

Arcus Biosciences (NYSE:RCUS) shares ticked up 0.41% to $15.85 on Friday, on Volume of about 705,540 shares, near the 52-week low of $15.63. Investors are weighing strong casdatifan data in kidney cancer and a cash runway into 2029 against a post-offering slide, shrinking collaboration revenue and a weak risk backdrop.

Arcus is a clinical-stage biotechnology company with a net loss per share of $3.90 over the past year.

Wider Third-Quarter Loss and a $250 Million Offering

The company priced a $250 million stock offering in October and reported a third-quarter loss of $1.00 per share, wider than expected, on revenue of $9 million, down from $26 million a year earlier.

Analyst targets remain far above the share price. The consensus is about $41, and Leerink raised its target to $49.

Conferences and PEAK-1 Enrollment Are the Next Markers

Management will present at conferences on Dec. 1 and 2, and enrollment in the Phase 3 PEAK-1 trial is expected to finish within two to three months.

Biotech peers were mixed. Arcutis Biotherapeutics (NASDAQ:ARQT) fell 1.73%, Legend Biotech (NASDAQ:LEGN) dropped 4.72%, Xencor (NASDAQ:XNCR) slipped 1.17% and Beam Therapeutics (NASDAQ:BEAM) gained 2.01%. The 52-week range runs from $15.63 to $31.74.

PEAK-1 Enrollment Completion Could Reset the Narrative

Arcus trades near its low despite clinical progress and a funded runway. Investors will watch the December conferences and completion of PEAK-1 enrollment.